Subtopic Deep Dive
Citicoline in Ischemic Stroke
Research Guide
What is Citicoline in Ischemic Stroke?
Citicoline is a neuroprotective agent studied for reducing ischemic lesion growth and improving functional outcomes in acute ischemic stroke patients.
Clinical trials have evaluated citicoline administered orally or intravenously in acute ischemic stroke, showing potential benefits in limiting infarct expansion via diffusion-weighted MRI (Warach et al., 2000, 231 citations). Randomized trials demonstrated improved recovery scores compared to placebo (Clark et al., 1999, 231 citations; Dávalos et al., 2002, 229 citations). Over 10 key papers from 1999-2018 explore its mechanisms and efficacy, with mixed results on neuroprotection.
Why It Matters
Citicoline targets free radical damage and membrane stabilization in ischemia-reperfusion injury, a barrier to effective revascularization in stroke (Sun et al., 2018). It shows promise in reducing post-stroke cognitive impairment affecting up to one-third of survivors (Mijajlović et al., 2017). Clinical applications include adjunct therapy to thrombolysis, potentially enhancing neuronal repair and functional recovery in elderly patients (Corrao et al., 2016).
Key Research Challenges
Inconsistent Clinical Efficacy
Trials show variable outcomes on functional recovery, with some reporting no significant benefit over placebo (Clark et al., 1999). Differences in dosing, timing, and patient selection contribute to mixed results (Dávalos et al., 2002). Larger meta-analyses are needed to resolve discrepancies.
Translating Neuroprotection
Preclinical mechanisms like free radical scavenging do not always translate to human trials (Adibhatla et al., 2001). Ischemia-reperfusion injury limits efficacy post-revascularization (Sun et al., 2018). Optimal windows for administration remain unclear (Green, 2007).
Measuring Lesion Changes
Diffusion-weighted MRI reveals lesion growth reduction, but long-term outcomes vary (Warach et al., 2000). Cognitive endpoints like post-stroke dementia complicate assessment (Mijajlović et al., 2017). Standardized imaging and functional scales are required.
Essential Papers
Post-stroke dementia – a comprehensive review
Milija Mijajlović, Aleksandra Pavlović, Michael Brainin et al. · 2017 · BMC Medicine · 660 citations
Post-stroke dementia (PSD) or post-stroke cognitive impairment (PSCI) may affect up to one third of stroke survivors. Various definitions of PSCI and PSD have been described. We propose PSD as a la...
Free Radical Damage in Ischemia‐Reperfusion Injury: An Obstacle in Acute Ischemic Stroke after Revascularization Therapy
Ming-Shuo Sun, Hang Jin, Xin Sun et al. · 2018 · Oxidative Medicine and Cellular Longevity · 475 citations
Acute ischemic stroke is a common cause of morbidity and mortality worldwide. Thrombolysis with recombinant tissue plasminogen activator and endovascular thrombectomy are the main revascularization...
Effect of citicoline on ischemic lesions as measured by diffusion‐weighted magnetic resonance imaging
S. Warach, L. Creed Pettigrew, John F. Dashe et al. · 2000 · Annals of Neurology · 231 citations
We examined the effect of the neuroprotective and neuroreparative agent citicoline on the growth of cerebral ischemic lesions in a double-blind placebo-controlled study involving patients with acut...
A Randomized Efficacy Trial of Citicoline in Patients With Acute Ischemic Stroke
Wayne M. Clark, Benjamin J. Williams, Kenneth A. Selzer et al. · 1999 · Stroke · 231 citations
Background and Purpose —Citicoline (cytidine-5′-diphosphocholine; CDP-choline) may reduce central nervous system ischemic injury by stabilizing cell membranes and reducing free radical generation. ...
Oral Citicoline in Acute Ischemic Stroke
Antoni Dávalos, José Castillo, José Álvarez‐Sabín et al. · 2002 · Stroke · 229 citations
Background and Purpose— No single neuroprotective agent has been shown to influence outcome after acute stroke. Citicoline has been studied worldwide in many clinical trials with positive findings,...
Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke
María Gutiérrez‐Fernández, Berta Rodríguez‐Frutos, Jaime Ramos‐Cejudo et al. · 2013 · Stem Cell Research & Therapy · 221 citations
Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly
A R Green · 2007 · British Journal of Pharmacology · 177 citations
Stroke is a major cause of both death and disability. However, there are no pharmacological treatments used in most countries other than recombinant tissue plasminogen activator, a thrombolytic, an...
Reading Guide
Foundational Papers
Start with Warach et al. (2000) for MRI evidence of lesion reduction; Clark et al. (1999) for first RCT on efficacy; Dávalos et al. (2002) for oral administration outcomes—these establish core clinical data (231, 231, 229 citations).
Recent Advances
Mijajlović et al. (2017, 660 citations) on post-stroke dementia links; Sun et al. (2018, 475 citations) on reperfusion challenges—contextualize citicoline in modern stroke care.
Core Methods
RCTs with placebo controls measure infarct growth via DWI-MRI (Warach et al., 2000); neurochemical assays assess membrane repair and free radical reduction (Adibhatla et al., 2001); functional scales like NIHSS track recovery (Clark et al., 1999).
How PapersFlow Helps You Research Citicoline in Ischemic Stroke
Discover & Search
Research Agent uses searchPapers and citationGraph to map citicoline trials from Warach et al. (2000), revealing clusters around Clark et al. (1999) and Dávalos et al. (2002); exaSearch uncovers related neuroprotection studies like Sun et al. (2018); findSimilarPapers expands to post-stroke cognition from Mijajlović et al. (2017).
Analyze & Verify
Analysis Agent applies readPaperContent to extract trial data from Clark et al. (1999), then runPythonAnalysis with pandas to compare recovery scores across studies; verifyResponse (CoVe) checks claims against GRADE grading for evidence strength in neuroprotective efficacy; statistical verification confirms lesion reduction significance from Warach et al. (2000).
Synthesize & Write
Synthesis Agent detects gaps in consistent efficacy between preclinical (Adibhatla et al., 2001) and clinical data (Dávalos et al., 2002); Writing Agent uses latexEditText and latexSyncCitations to draft reviews, latexCompile for publication-ready manuscripts, and exportMermaid for trial outcome flowcharts.
Use Cases
"Run meta-analysis on citicoline trial recovery scores vs placebo"
Research Agent → searchPapers (citicoline stroke trials) → Analysis Agent → readPaperContent (Clark 1999, Dávalos 2002) → runPythonAnalysis (pandas meta-analysis plot) → researcher gets CSV of pooled odds ratios and forest plot.
"Draft review section on citicoline MRI outcomes with citations"
Synthesis Agent → gap detection (Warach 2000 inconsistencies) → Writing Agent → latexEditText (insert text) → latexSyncCitations (add Warach, Clark) → latexCompile → researcher gets compiled LaTeX PDF with synced references.
"Find code for ischemic stroke lesion simulation models"
Research Agent → searchPapers (ischemic stroke models) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets annotated GitHub repos simulating citicoline effects from Adibhatla-inspired free radical models.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ citicoline papers: searchPapers → citationGraph → GRADE grading → structured report on efficacy trends. DeepScan applies 7-step analysis to Warach et al. (2000): readPaperContent → CoVe verification → runPythonAnalysis on MRI data. Theorizer generates hypotheses on citicoline timing from Green (2007) and Sun (2018) mechanisms.
Frequently Asked Questions
What is citicoline in ischemic stroke?
Citicoline (CDP-choline) is a neuroprotectant that stabilizes membranes and reduces free radicals in acute stroke (Adibhatla et al., 2001).
What methods test citicoline efficacy?
Double-blind RCTs use diffusion-weighted MRI for lesion growth (Warach et al., 2000) and NIHSS scores for recovery (Clark et al., 1999; Dávalos et al., 2002).
What are key papers on citicoline?
Warach et al. (2000, 231 citations) on MRI lesions; Clark et al. (1999, 231 citations) and Dávalos et al. (2002, 229 citations) on clinical trials.
What open problems exist?
Inconsistent trial outcomes require meta-analyses; optimal dosing and combination with reperfusion therapies need study (Sun et al., 2018; Green, 2007).
Research Neurological Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Neuroscience researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Systematic Review
AI-powered evidence synthesis with documented search strategies
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Citicoline in Ischemic Stroke with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Neuroscience researchers